Chimeric antigen receptor T (CAR-T) cell therapy is another type of ROR1-targeted therapeutic approach that has been explored, with the advantage of low off-target cytotoxicity due to the aforementioned unique expression of ROR1 in cancer cells, such as CLL and MCL cells, but not in normal B cells [136]. This evidence concerns the gene ROR1 and cancer.